) Egetis Therapeutics AB (publ) has carried out a directed new share issue of shares of approximately SEK 350 million where the subscription price was set through an accelerated bookbuilding procedure ... EGTX) ... AttachmentsOriginal document Permalink.
Subscription undertakings from the Company's two major shareholders, Board of Directors, management and other larger shareholders amount to approximately SEK 9.3 million, corresponding to approximately 31 percent of the Rights Issue.
2026-04-23 21.34.00 CEST Ascelia Pharma AB - Inside information Ascelia Pharma Carries Out a Directed Share Issue of SEK 20 Million ... Ascelia Pharma Carries Out a Directed Share Issue of SEK 20 ...
) Arctic Minerals has completed a directed share issue and raises proceeds of approximately SEK 40 million ...The Company will hereby receive a total of approximately SEK 40 million before costs related to the Directed Share Issue.
Smoltek strengthens liquidity by raising a loan of SEK 11 million with a conversion option ... Smoltek Nanotech Holding AB (publ) ("Smoltek" or "the Company") has today entered into a loan agreement totaling SEK 11 million.
This emerging paradigm challenges conventional currency valuation models that have dominated SEK trading strategies for decades. SEK CurrencyAnalysis... Nordea’s latest research reveals a significant shift in SEK valuation drivers.
Danske Bank, one of Scandinavia’s leading financial institutions, has decided to maintain its EUR/SEK forecast profile unchanged, signaling a period of relative stability in the Euro-Swedish Krona exchange rate as we move through 2025.
To ensure the company's liquidity until the company has received proceeds from the planned rights issue, the company has received bridge loan facilities from the main owners totalling approximately SEK 4 million.
2026-04-13 07.00.00 CEST Enad Global 7 AB - Other information disclosed according to the rules of the Exchange EG7 implements organizational realignment which is expected to reduce annual costs by SEK 32 million from Q2 2026.